FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3193474047> ?p ?o ?g. }

• W3193474047 endingPage "2149" @default.
• W3193474047 startingPage "2143" @default.
• W3193474047 abstract "Introduction Infliximab remains a mainstay for treatment of inflammatory bowel disease (IBD), but a long infusion duration and subsequent monitoring can be burdensome to patients and health care providers. We assessed the safety of accelerated infusions for standard and dose-intensified infliximab regimens, and the effect on patient satisfaction and potential cost savings. Methods Patients with IBD on a stable maintenance dose of infliximab and in clinical remission received one or more accelerated infusions; over 30 min if receiving standard-dose (5 mg/kg), or over 60 min if receiving dose-intensified infliximab (up to 10 mg/kg). Outcomes included incidence of reactions (acute or delayed), patient satisfaction, and potential cost savings. We also explored infliximab trough levels after one and three accelerated infusions. Results 52 patients who received 150 infusions were studied. Incidence of reactions to accelerated infusions was 3.3% (3 out of 89) with standard-dose and 0% (out of 61) with dose-intensified infliximab. Reactions were delayed, mild, and self-limiting. None requiring drug cessation. Patient satisfaction was improved with shortened infusion time as compared to the patients’ previous experiences (p = 0.00002). Mean plasma trough level of infliximab reduced from 9.3 mg/L (± 4.9) to 7.9 mg/L (± 4.1) (p = 0.02) with accelerated infusions, but none developed anti-infliximab antibodies. Nursing cost savings were estimated as $123.52 and $247.04 per-patient per-year for standard and dose-intensified infliximab, respectively. Conclusion Accelerated infliximab infusions for standard and dose-intensified regimens seems to be safe and improved patient satisfaction. Potential impact on drug trough levels requires further investigations. This article is protected by copyright. All rights reserved." @default.
• W3193474047 created "2021-08-30" @default.
• W3193474047 creator A5015189008 @default.
• W3193474047 creator A5018410496 @default.
• W3193474047 creator A5026362042 @default.
• W3193474047 creator A5041874315 @default.
• W3193474047 creator A5050804872 @default.
• W3193474047 creator A5053863653 @default.
• W3193474047 creator A5079247509 @default.
• W3193474047 date "2022-06-30" @default.
• W3193474047 modified "2023-09-30" @default.
• W3193474047 title "Safety, satisfaction and cost savings of accelerated infusions of standard and intensified‐dose infliximab for inflammatory bowel disease" @default.
• W3193474047 cites W2002048963 @default.
• W3193474047 cites W2003573251 @default.
• W3193474047 cites W2003904406 @default.
• W3193474047 cites W2010872383 @default.
• W3193474047 cites W2026465577 @default.
• W3193474047 cites W2031193040 @default.
• W3193474047 cites W2035554099 @default.
• W3193474047 cites W2056161490 @default.
• W3193474047 cites W2064527996 @default.
• W3193474047 cites W2093372305 @default.
• W3193474047 cites W2099169909 @default.
• W3193474047 cites W2139133180 @default.
• W3193474047 cites W2165107045 @default.
• W3193474047 cites W2171297959 @default.
• W3193474047 cites W2235306358 @default.
• W3193474047 cites W2550643857 @default.
• W3193474047 cites W2744879509 @default.
• W3193474047 cites W2764071025 @default.
• W3193474047 cites W2782782475 @default.
• W3193474047 cites W3149527659 @default.
• W3193474047 cites W4210662453 @default.
• W3193474047 cites W4211167126 @default.
• W3193474047 cites W774488534 @default.
• W3193474047 doi "https://doi.org/10.1111/imj.15493" @default.
• W3193474047 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34405958" @default.
• W3193474047 hasPublicationYear "2022" @default.
• W3193474047 type Work @default.
• W3193474047 sameAs 3193474047 @default.
• W3193474047 citedByCount "2" @default.
• W3193474047 countsByYear W31934740472022 @default.
• W3193474047 countsByYear W31934740472023 @default.
• W3193474047 crossrefType "journal-article" @default.
• W3193474047 hasAuthorship W3193474047A5015189008 @default.
• W3193474047 hasAuthorship W3193474047A5018410496 @default.
• W3193474047 hasAuthorship W3193474047A5026362042 @default.
• W3193474047 hasAuthorship W3193474047A5041874315 @default.
• W3193474047 hasAuthorship W3193474047A5050804872 @default.
• W3193474047 hasAuthorship W3193474047A5053863653 @default.
• W3193474047 hasAuthorship W3193474047A5079247509 @default.
• W3193474047 hasConcept C120665830 @default.
• W3193474047 hasConcept C121332964 @default.
• W3193474047 hasConcept C126322002 @default.
• W3193474047 hasConcept C141071460 @default.
• W3193474047 hasConcept C197934379 @default.
• W3193474047 hasConcept C2777138892 @default.
• W3193474047 hasConcept C2778260677 @default.
• W3193474047 hasConcept C2779134260 @default.
• W3193474047 hasConcept C61511704 @default.
• W3193474047 hasConcept C71924100 @default.
• W3193474047 hasConceptScore W3193474047C120665830 @default.
• W3193474047 hasConceptScore W3193474047C121332964 @default.
• W3193474047 hasConceptScore W3193474047C126322002 @default.
• W3193474047 hasConceptScore W3193474047C141071460 @default.
• W3193474047 hasConceptScore W3193474047C197934379 @default.
• W3193474047 hasConceptScore W3193474047C2777138892 @default.
• W3193474047 hasConceptScore W3193474047C2778260677 @default.
• W3193474047 hasConceptScore W3193474047C2779134260 @default.
• W3193474047 hasConceptScore W3193474047C61511704 @default.
• W3193474047 hasConceptScore W3193474047C71924100 @default.
• W3193474047 hasIssue "12" @default.
• W3193474047 hasLocation W31934740471 @default.
• W3193474047 hasLocation W31934740472 @default.
• W3193474047 hasOpenAccess W3193474047 @default.
• W3193474047 hasPrimaryLocation W31934740471 @default.
• W3193474047 hasRelatedWork W1464824982 @default.
• W3193474047 hasRelatedWork W1793302197 @default.
• W3193474047 hasRelatedWork W2022117977 @default.
• W3193474047 hasRelatedWork W2132711226 @default.
• W3193474047 hasRelatedWork W2156758733 @default.
• W3193474047 hasRelatedWork W2297514571 @default.
• W3193474047 hasRelatedWork W2576474053 @default.
• W3193474047 hasRelatedWork W2941983942 @default.
• W3193474047 hasRelatedWork W4205456923 @default.
• W3193474047 hasRelatedWork W4226198071 @default.
• W3193474047 hasVolume "52" @default.
• W3193474047 isParatext "false" @default.
• W3193474047 isRetracted "false" @default.
• W3193474047 magId "3193474047" @default.
• W3193474047 workType "article" @default.